Market Overview:
The global pneumococcal vaccine polyvalent market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of pneumococcal diseases, rising demand for pneumococcal vaccines, and technological advancements in the field of vaccine development. Based on type, the global pneumococcal vaccine polyvalent market is segmented into Prevnar 13 and Pneumovax23. Prevnar 13 accounted for a larger share of the market in 2017 and is expected to maintain its dominance during the forecast period. This can be attributed to its high efficacy and safety profile as compared to other available vaccines. Based on application, the global pneumococcal vaccine polyvalent market is segmented into 18 years and younger, 19 To 64 years old, 65 years and older segments.
Product Definition:
A pneumococcal vaccine is a vaccine that protects against infection by the bacterium Streptococcus pneumoniae, which can cause pneumonia, meningitis and other diseases. Pneumococcal vaccines are usually given to children as part of routine vaccinations, but may also be given to adults.
Prevnar 13:
Prevnar 13 is a new variant of the Prevnar 7, first approved in Europe in 2013. It was approved by the U.S. FDA for pediatric use in 2015 and adult use in 2016. The product label now includes indications for adults as well as children above 2 years of age, making it one of the few vaccines with a single-dose formulation that is licensed for both pediatrics and adults across all major markets (U.S., EU5 countries, Japan).
Pneumovax23:
Pneumovax23 is a live attenuated vaccine developed by GlaxoSmithKline Biologicals for use in the Pneumococcal Vaccine Polyvalent (PCV) market. It was approved by the FDA and EMA in 1995 as an alternative to PCV7, which was then the only commercially available pneumococcal vaccine.
Application Insights:
In terms of application, the global pneumococcal vaccine polyvalent market is categorized into 18 years and younger, 19 to 64 years old and 65 years and older. The 18-year-olds segment held the largest share in 2017. This is attributed to high incidence rates of diseases such as chickenpox among this age group across the globe. Moreover, a growing number of immunization programs against Pneumovax23 has also positively influenced its demand from this segment over the past few years.
The 19-to 64-year olds segment is expected to witness significant growth during forecast period owing to increasing awareness about vaccination among working professionals in developed economies including U.S., Canada, U.K.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing disease burden, rising immunization coverage, and availability of a robust healthcare infrastructure. Moreover, high investment by government organizations for research & development activities is also anticipated to drive growth in this region.
Asia Pacific is estimated to be the fastest-growing regional segment over the forecast period owing to improving immunization programs and growing target population base. In addition, increasing prevalence of pneumococcal diseases coupled with rising awareness about vaccination programs will support regional growth during the same period.
Latin America held a considerable share owing to high unmet clinical needs pertaining towards prevention & control of pneumococcal diseases along with favorable demographic factors such as aging population.
Growth Factors:
- Increasing incidence of pneumococcal infections: The global incidence of pneumococcal infections is increasing due to the rise in the number of elderly and immunocompromised individuals. This is expected to drive the demand for pneumococcal vaccines in the coming years.
- Growing awareness about pneumococcal diseases: There is a growing awareness among people about the dangers posed by pneumococcal diseases such as pneumonia, meningitis, and sepsis. This is likely to boost demand for pneumococcal vaccines in the near future.
- Technological advancements in vaccine development: The development of new and innovative technologies for vaccine production has led to an increase in uptake rates for various types of vaccines including polyvalent pneumococcal vaccines. This trend is likely to continue in the foreseeable future, propelling growth prospects for this market segment.
Scope Of The Report
Report Attributes
Report Details
Report Title
Pneumococcal Vaccine Polyvalent Market Research Report
By Type
Prevnar 13, Pneumovax23
By Application
18 Years and Younger, 19 To 64 Years Old, 65 Years and Older
By Companies
Merck & Co., Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
152
Number of Tables & Figures
107
Customization Available
Yes, the report can be customized as per your need.
Global Pneumococcal Vaccine Polyvalent Market Report Segments:
The global Pneumococcal Vaccine Polyvalent market is segmented on the basis of:
Types
Prevnar 13, Pneumovax23
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
18 Years and Younger, 19 To 64 Years Old, 65 Years and Older
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck & Co.
- Pfizer
Highlights of The Pneumococcal Vaccine Polyvalent Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Prevnar 13
- Pneumovax23
- By Application:
- 18 Years and Younger
- 19 To 64 Years Old
- 65 Years and Older
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pneumococcal Vaccine Polyvalent Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pneumococcal vaccine polyvalent is a vaccine that protects against three types of pneumococcus bacteria: Streptococcus pneumoniae, Haemophilus influenzae type b (Hib), and Moraxella catarrhalis.
Some of the major players in the pneumococcal vaccine polyvalent market are Merck & Co., Pfizer.
The pneumococcal vaccine polyvalent market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pneumococcal Vaccine Polyvalent Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Pneumococcal Vaccine Polyvalent Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Pneumococcal Vaccine Polyvalent Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Pneumococcal Vaccine Polyvalent Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Pneumococcal Vaccine Polyvalent Market Size & Forecast, 2018-2028
4.5.1 Pneumococcal Vaccine Polyvalent Market Size and Y-o-Y Growth
4.5.2 Pneumococcal Vaccine Polyvalent Market Absolute $ Opportunity
Chapter 5 Global Pneumococcal Vaccine Polyvalent Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Pneumococcal Vaccine Polyvalent Market Size Forecast by Type
5.2.1 Prevnar 13
5.2.2 Pneumovax23
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Pneumococcal Vaccine Polyvalent Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Pneumococcal Vaccine Polyvalent Market Size Forecast by Applications
6.2.1 18 Years and Younger
6.2.2 19 To 64 Years Old
6.2.3 65 Years and Older
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Pneumococcal Vaccine Polyvalent Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Pneumococcal Vaccine Polyvalent Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Pneumococcal Vaccine Polyvalent Analysis and Forecast
9.1 Introduction
9.2 North America Pneumococcal Vaccine Polyvalent Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Pneumococcal Vaccine Polyvalent Market Size Forecast by Type
9.6.1 Prevnar 13
9.6.2 Pneumovax23
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Pneumococcal Vaccine Polyvalent Market Size Forecast by Applications
9.10.1 18 Years and Younger
9.10.2 19 To 64 Years Old
9.10.3 65 Years and Older
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Pneumococcal Vaccine Polyvalent Analysis and Forecast
10.1 Introduction
10.2 Europe Pneumococcal Vaccine Polyvalent Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Pneumococcal Vaccine Polyvalent Market Size Forecast by Type
10.6.1 Prevnar 13
10.6.2 Pneumovax23
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Pneumococcal Vaccine Polyvalent Market Size Forecast by Applications
10.10.1 18 Years and Younger
10.10.2 19 To 64 Years Old
10.10.3 65 Years and Older
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Pneumococcal Vaccine Polyvalent Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Pneumococcal Vaccine Polyvalent Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Pneumococcal Vaccine Polyvalent Market Size Forecast by Type
11.6.1 Prevnar 13
11.6.2 Pneumovax23
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Pneumococcal Vaccine Polyvalent Market Size Forecast by Applications
11.10.1 18 Years and Younger
11.10.2 19 To 64 Years Old
11.10.3 65 Years and Older
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Pneumococcal Vaccine Polyvalent Analysis and Forecast
12.1 Introduction
12.2 Latin America Pneumococcal Vaccine Polyvalent Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Pneumococcal Vaccine Polyvalent Market Size Forecast by Type
12.6.1 Prevnar 13
12.6.2 Pneumovax23
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Pneumococcal Vaccine Polyvalent Market Size Forecast by Applications
12.10.1 18 Years and Younger
12.10.2 19 To 64 Years Old
12.10.3 65 Years and Older
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Pneumococcal Vaccine Polyvalent Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Pneumococcal Vaccine Polyvalent Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Pneumococcal Vaccine Polyvalent Market Size Forecast by Type
13.6.1 Prevnar 13
13.6.2 Pneumovax23
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Pneumococcal Vaccine Polyvalent Market Size Forecast by Applications
13.10.1 18 Years and Younger
13.10.2 19 To 64 Years Old
13.10.3 65 Years and Older
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Pneumococcal Vaccine Polyvalent Market: Competitive Dashboard
14.2 Global Pneumococcal Vaccine Polyvalent Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck & Co.
14.3.2 Pfizer
